Bibliografía
1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-30. DOI: 10.1136/annrheumdis-2013-204763.
2. Seoane-Mato D, Sánchez-Piedra C, Silva-Fernández L, Sivera F, Blanco FJ, Pérez Ruiz F, et al. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology. Reumatol Clin. 2019;15(2):90-6. DOI: 10.1016/j.reuma.2017.06.009.
3. Blanco FJ, Silva-Díaz M, Quevedo Vila V, Seoane-Mato D, Pérez Ruiz F, Juan-Mas A, et al. Prevalence of Symptomatic Osteoarthritis in Spain: EPISER2016 Study. Reumatol Clin. 2020; S1699-258X(20)30023-1. DOI: 10.1016/j.reuma.2020.01.008.
4. Hermans J, Koopmanschap MA, Bierma-Zeinstra SM, van Linge JH, Verhaar JA, Reijman M, et al. Productivity costs and medical costs among working patients with knee osteoarthritis. Arthritis Care Res (Hoboken). 2012;64(6):853-61. DOI: 10.1002/acr.21617.
5. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437-41. DOI: 10.1038/nrrheum.2014.44.
6. Le Pen C, Reygrobellet C, Gerentes I. Financial cost of osteoarthritis in France. The "COART" France study. Jt Bone Spine. 2005;72(6):567-70. DOI: 10.1016/j.jbspin.2005.01.011.
7. 7)Kingsbury SR, Gross HJ, Isherwood G, Conaghan PG. Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countries. Rheumatology (Oxford) 2014;53(5):937-47. DOI: 10.1093/rheumatology/ket463.
8. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64(4):465-74. DOI: 10.1002/acr.21596.
9. Zhang W, Doherty M, Arden N, Bannwarth B, Bijlsma J, Gunther KP, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005;64(5):669-81. DOI: 10.1136/ard.2004.028886.
10. Fernandes L, Hagen KB, Bijlsma JW, Andreassen O, Christensen P, Conaghan PG, et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis. 2013;727):1125-35. DOI: 10.1136/annrheumdis-2012-202745.
11. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-89. DOI: 10.1016/j.joca.2019.06.011.
12. NICE. Osteoarthritis: care and management [Internet]. National Institute for Health and Care Excellence; 2020 [Consultada el día 4 de noviembre de 2020]. Disponible en: www.nice.org.uk/guidance/cg177.
13. Basedow M, Esterman A. Assessing appropriateness of osteoarthritis care using quality indicators: a systematic review. J Eval Clin Pract. 2015;21(5):782-9. DOI: 10.1111/jep.12402.
14. García del, Pozo J, Carvajal A, Rueda De Castro AM, Cano Del Pozo MI, et al. Opioid consumption in Spain - the significance of a regulatory measure. Eur J Clin Pharmacol. 1999;55(9):681-3. DOI: 10.1007/s002280050693.
15. Wright EA, Katz JN, Abrams S, Solomon DH, Losina E. Trends in Prescription of Opioids From 2003-2009 in Persons With Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2014;66(10):1489-95. DOI: 10.1002/acr.22360.
16. Häuser W, Schubert T, Scherbau N, Tölle T. Guideline recommended vs high-dose long-term opioid therapy for chronic noncancer pain is associated with better health outcomes: data from a representative sample of the German population. Pain. 2018;159(1):85-91. DOI: 10.1097/j.pain.0000000000001067.
17. Ashburn MA, Fleisher, LA. Increasing evidence for the limited role of opioids to treat chronic noncancer pain. JAMA. 2018;320(23):2427-28. DOI: 10.1001/jama.2018.19327.
18. Dasgupta N, Beletsky L, Ciccarone D. Opioid crisis: No easy fix to its social and economic determinants. Am J Public Health. 2018;108(2):182-6. DOI: 10.2105/AJPH.2017.304187.
19. Welsch P, Petzke F, Klose P, Häuser W. Opioids for chronic osteoarthritis pain: An updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. Eur J Pain. 2020;24(4):685-703. DOI: 10.1002/ejp.1522.
20. Afilalo M, Etropolski MS, Kuperwasser B, Kelly K, Okamoto A, Van Hove I, et al. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489-505. DOI: 10.2165/11533440-000000000-00000.
21. Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013;16(1):27-40.
22. Santos J, Alarcão J, Fareleira F, Vaz-Carneiro A, Costa, J. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015;2015(5):CD009923. DOI: 10.1002/14651858.CD009923.pub2.
23. Cicero TJ, Inciardi JA, Muñoz A. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain. 2005;6(10):662-72. DOI: 10.1016/j.jpain.2005.05.004.
24. 24)Bialas P, Maier C, Klose P, Hauser W. Efficacy and harms of long-term opioid therapy in chronic noncancerpain: Systematic review and meta-analysis of open-label extension trials with a study duration ≥26 weeks. Eur J Pain. 2020;24(2):265-78. DOI: 10.1002/ejp.1496.
25. Sicras-Mainar A, Tornero-Tornero C, Vargas-Negrín F, Lizarraga I, Rejas-Gutierrez J. Health outcomes and costs in patients with osteoarthritis and chronic pain treated with opioids in Spain: the OPIOIDS real-world study. Ther Adv Musculoskel Dis. 2020;12:1-18. DOI: 10.1177/1759720X20942000.
26. Megale RZ, Deveza LA, Blyth FM, Naganathan V, Ferreira PH, McLachlan AJ, et al. Efficacy and Safety of Oral and Transdermal Opioid Analgesics for Musculoskeletal Pain in Older Adults: A Systematic Review of Randomized, Placebo-Controlled Trials. J Pain. 2018;19(5):475.e1-475.e24. DOI: 10.1016/j.jpain.2017.12.001.
27. Smith SR, Deshpande BR, Collins JE, Katz JN, Losina E. Comparative pain reduction of oral non-steroidal anti-inflammatory drugs and opioids for knee osteoarthritis: systematic analytic review. Osteoarthr Cartil. 2016;24(6):962-72. DOI: 10.1016/j.joca.2016.01.135.
28. Schaefert R, Welsch P, Klose P, Sommer C, Petzke F, Häuser W. Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks. Schmerz. 2015;29(1):47-59. DOI: 10.1007/s00482-014-1451-1.
29. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: The SPACE randomized clinical tiral. JAMA. 2018;319(9):872-82. DOI: 10.1001/jama.2018.0899.
30. Massaly N, Morón JA. Pain And Opioid Systems, Implications In The Opioid Epidemic. Curr Opin Behav Sci. 2019;26:69-74. DOI: 10.1016/j.cobeha.2018.10.002.
31. Zeng C, Dubreuil M, LaRochelle MR, Lu N, Wei J, Choi HK, et al. Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA. 2019;321(10):969-82. DOI: 10.1001/jama.2019.1347.
32. Kostev K, Wartenberg F, Richter H, Reinwald M, Heilmaier C. Persistence with opioid treatment in Germany in patients suffering from chronic non-malignant or cancer pain. Curr Med Res Opinion. 2015;31(6,)1157-63. DOI: 10.1185/03007995.2015.1034095.
33. Scherbakova N, Tereso G, Spain J. Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder. Ann Pharmacother. 2018;52(5):405-14. DOI: 10.1177/1060028017751913.
34. Lalic S, Gisev N Bell JS, Korhonen MJ, Ilomäki J. Predictors of persistent prescription opioid analgesic use among people without cancer in Australia. Br J Clin Pharmacol. 2018;84(6):1267-78. DOI: 10.1111/bcp.13556.
35. Fuggle N, Curtis E, Shaw S, Spooner L, Bruyère O, Ntani G, et al. Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):129-43. DOI: 10.1007/s40266-019-00666-9.
36. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, et al. Guideline for opioid therapy and. chronic noncancer pain. CMAJ. 2017;189(18):E659-E666. DOI: 10.1503/cmaj.170363.
37. Dowell D, Haegerich TM, Chou R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624-45. DOI: 10.1001/jama.2016.1464.
38. Moisset X, Martinez V. Opioid use for the management of chronic non-cancer pain: French guidelines. Rev Neurol. 2016;172(6-7):337-8. DOI: 10.1016/j.neurol.2016.05.004.
39. O'Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJm et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3-19. DOI: 10.1002/ejp.970.
40. Deveza LA, Hunter DJ, Van Spil WE. Too much opioid, too much harm. Osteoarthritis Cartilage. 2018;26(3):293-5. DOI: 10.1016/j.joca.2017.12.003.
41. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569-76. DOI: 10.1097/01.j.pain.0000460357.01998.f1.
42. da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, et al. Oral or transdermal opioids for osteoarthritis. of the knee or hip. Cochrane Database Syst Rev. 2014;(9).Cd003115.
Artículos relacionados
Abstracts
Rev. Soc. Esp. Dolor. 2023; 30(13): 3-169
Pain: a "hotchpotch"
Rev. Soc. Esp. Dolor. 2020; 27(4): 278-280 / DOI: 10.20986/resed.2016.3507/2016